NEARLY 4,500 PEOPLE HAVE BENEFITED FROM ESTEVE’S SOCIAL AND WELFARE INITIATIVES
According to data published in its 2013 Sustainability Report
Barcelona, 11th July 2014. ESTEVE's 2013 Sustainability Report has again received an "A+" rating, thus becoming the only pharmaceutical company in Spain to earn this consideration for the seventh consecutive year. The "A+" rating is awarded by the Global Reporting Initiative (GRI), an international independent body that leads and supports the provision of transparent, verifiable information by companies on their own activities. This rating also implies that ESTEVE's 2013 Report contains the maximum number of GRI-established indicators, and that these values have been certified by an external company.
Aid to the most deprived
ESTEVE carries out different welfare initiatives, both in developing countries and in the most vulnerable populations of our country. Thus, in 2013, 4,490 people in total benefited from ESTEVE's collaboration with 23 non-profit organizations such as food banks and Cáritas, among others.
ESTEVE also adheres to the ten principles of the Global Compact and the Millennium Development Goals established by the United Nations. In this context, the company has set up a new model of medicine donations to hospitals, dispensaries, mother and child centres, accommodation facilities for sick people, orphanages and nursing homes in developing countries. In total, 37 expeditions to 21 different countries through 33 NGOs were carried out in 2013.
ESTEVE also participates in Farmamundi's Humanitarian and Emergency Aid Fund (FAHE), which in 2013 benefited 96,168 people through 10 interventions in 8 countries around the globe. These included emergency interventions in Kenya, Syria and the Philippines; post-emergency interventions in Mali and the Dominican Republic; and humanitarian aid in Palestine, the Democratic Republic of the Congo, and Uganda.
In 2013, industrial expenses and investments made according to efficiency criteria in different centres, as well as different public awareness campaigns, have allowed reducing CO2 emissions by 15%, that is, by 4,159 tons.
ESTEVE has also compensated for 375 tons of CO2 by means of a reforestation project in Chiapas (Mexico), where ESTEVE has a chemical plant. This project has been promoted by ECODES in the framework of the Zero CO2 Challenge, which also provides other environmental (preservation of biodiversity) and social (cooperation to the development of the most vulnerable populations) benefits.
Learn more at: ESTEVE Sustainability Report 2013
THE PROGRAM ’PLAN PROFARMA’ HAS ONCE AGAIN QUALIFIED ESTEVE’S R&D&I AS ’’EXCELLENT’’
Once again, ESTEVE's research activity has received the qualification ''Excellent'' in the Program 'Plan Profarma' (Program for Fostering Scientific Research, Technological Development and Innovation ...read more
PENSA PHARMA HAS BEEN AWARDED A PRIZE FOR ITS BEST DEVELOPMENT AND COMMERCIALIZATION OF GENERIC MEDICINES
Pensa Pharma (PENSA), a company of the ESTEVE Group specialized in generic medicines, has been awarded a prize at the II edition of La Razón Comunidad Valenciana Awards. Specifically, PENSA has receiv...read more
ESTEVE APPOINTS THOMAS B. RIISAGER AS CHIEF CORPORATE STRATEGY & BUSINESS DEVELOPMENT OFFICER
ESTEVE has announced today the appointment of Thomas B Riisager as Chief Corporate Strategy & Business Development Officer, to be heading Corporate Strategy & Business Development for the pharmaceutic...read more